ABSTRACT. Carnitine palmitoyltransferase deficiency re-clinical presentations: one with muscular (14), the other with alizes two distinct clinical forms. We previously showed hepatic (15) symptoms. The analysis of CPT activities of fibroand confirmed in the present work that CPTII (identified blasts from patients with muscular and hepatic forms of the as the carnitine palmitoyltransferase activity assayable in deficiency showed that CPTI deficiency was involved in the detergent conditions) is decreased in the muscular form hepatic form, whereas CPTII defect was evidenced in the muswhereas it is unaffected and CPTI is decreased in the cular form (16). hepatic form. The antibody previously prepared against CPT from human liver was purified from mitochondrial memhuman liver mitochondrial CPTII recognizes the same branes solubilized with Triton XlOO according to procedures enzyme in muscle, liver, and fibroblasts. Immunoprecipi-(17) that are thought to select (6-9) the protein that supports tation experiments were performed in fibroblasts from CPTII activity, and antibodies against this protein were raised in patients with the muscular and hepatic forms of the defect. rabbits (Demaugre F, Cepanec C, Leroux JP, unpublished data).
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DEMAUGRE ET AL Table 1 . CPT activities offibroblastsfvom patients with hepatic (A and B) and muscular (C and D) * CPT activities were assayed by the measurement of palmitoyl-L-(methyl 14C)carnitine formation from palmitoyl CoA and L-(methyl I4C)carnitine in three distinct assays as indicated in Materials and Methods. Assay I conducted in nondetergent conditions was performed on homogenate. Assays 11 and 111, respectively, performed on homogenate preincubated with 1 mM palmitoyl-D-carnitine and on 100 000 g supernatant of fibroblasts solubilized with 1 % Tween 20 in 0.5 M KC1 were carried out in detergent conditions. Results (mean + SD) are expressed as nmol of palmitoyl-L-(methyl 14C)carnitine produced . min-'/mg protein. n = number of different control cell lines. Three independent experiments were performed in deficient strains. Range of control values is given in parentheses.
Taken from Immunoprecipitation experiments. Immunoprecipitation experiments were performed as described by Fenton et al. (20) . 0.15 M NaCl, 10 mM EDTA, 0.2% SDS, and 10 mM KH2P04, pH 7.4, were added to 100 000 g supernatants of homogenates of muscle, liver, or fibroblasts, solubilized with 1 % Tween 20 in 500 mM NaCl. Aliquots (corresponding respectively to 300-500 fig, 600-1200 pg, and 600-1200 fig protein for liver, fibroblasts, and muscle), were then incubated with 0.5-2.0 fiL of preimmune or anti-CPT immune serum and 20 fiL of protein A Sepharose for 15 h at 4°C. Pellets of protein A Sepharose were washed four times with 0.5 M NaCI, 10 mM EDTA, 1% Tween 20, 0.1 % SDS, and 10 mM KH2P04, pH 7.4. proteins bound to protein A Sepharose were released by incubation of the pellets for 10 min at 100°C with 50 pL of 200 mM Tris, pH 6.8, containing 30% glycerol, 3% SDS, and 15% P-mercaptoethanol; they were analyzed by SDS-PAGE carried out as described (21) . Then proteins were electrotransferred to nitrocellulose sheets (22) . Treatment and revelation were performed as described (23) with .. ----patic CPT defect. Until now, only two patients have been diagnosed with this clinical form of CPT deficiency (15, 16) . We studied (16) CPT activities of fibroblasts from two patients with the muscular form and the only two patients diagnosed with the hepatic form. We showed that CPTI was decreased in patients with the hepatic form, whereas it was normal and CPTII decreased in patients with the muscular form. bfby)r &*aaAR homogenates As shown in from Table two We previously purified, according to the procedures described rabbits. Its mol wt, estimated by SDS-PAGE, was 66 000 D. It exhibits enzymatic activity (negligible with acetyl or butyryl CoA and maximal with lauryl CoA as substrates) in presence of detergents. This protein likely supports CPTII activity (discussed below). As shown in Figure 1 , IgG fraction of immune serum acts similarly on CPT activity measured in human liver, fibroblasts, and skeletal muscle solubilized with Tween 20; curves of suppression of CPT activity were similar in all tissues. In actual conditions of assay, more than 80% of CPT activity was suppressed at saturating concentration of Ig. Immunoprecipitation experiments followed by SDS-PAGE and Western blot were performed to analyze the material recognized bv immune serum. some modifications: nitrocellulose sheets were blocked 60 min at 37°C and 15 h at 4°C. Then they were incubated for 60 min at 37°C and overnight at 4°C with a 1/200 dilution of antiserum in the same buffer as for blocking. Protein was determined as described (24) .
Palmitoyl CoA, L-carnitine, malonyl CoA and BSA fatty acidfree were purchased from Sigma Chemical Co. 
RESULTS AND DISCUSSION
CPT deficiency realizes two different clinical forms. Most patients with CPT defect exhibit muscular symptoms (acute episodes of rhabdomyolysis after prolonged exercise or occasionally after fasting), which are ascribed to muscular deficiency (14) . Another clinical form of CPT deficiency (hepatic form) was diagnosed by Bougneres et al. (1 5) . It consists of hypoglycemia with inappropriate ketonemia during fasting, resulting from he-AS shown by Figure 2 , immune serum recognized in liver, fibroblasts, and muscle a single protein of electrophoretic mobility similar to that of purified CPT. These data suggest that the protein supporting CPT activity assayable in extracts solubilized with detergents-presumably CPTII-is similar if not identical in these tissues. Similar findings concerning CPTII of rat liver and muscle were reported by Woeltje et al. (9) .
Immunoprecipitation experiments (Fig. 3) were performed with fibroblasts from the two patients with the hepatic form and two patients with the muscular form of CPT deficiency. As compared with controls, immune serum recognized a single protein with normal electrophoretic mobility but in decreased amount in fibroblasts from patients with the muscular form of CPT deficiency. CRM estimated by densitometry was decreased by nearly 90% in cell line C and by more than 95% in cell line D. The amount of CRM correlated with the residual CPTII activity. CPTI was unaffected in these cells. This result suggests that immune serum only recognizes the protein supporting CPTII activity. One can postulate that the CPTII defect of these cells results from a decreased production of protein with normal affinity for the antibody, although a decreased afiinity for the DEMAUGF antibody cannot be excluded. Studies in progress capable of probing the intimate structure of CPT genes and mRNA are required to differentiate these possibilities.
In fibroblasts from patients with the hepatic form of the defect, immunoprecipitation experiments did not reveal any difference between controls and patients (Fig. 3) . Mutations causing the CPT defect exhibited by these cells (16; Table 1 ) do not affect the expression of the protein recognized by the immune serum, likely CPTII. The CRM of these cells does not correlate with the residual CPTI activity, but correlates with CPTII activity, which is unaffected.
The hypothesis of distinct proteins supporting CPTI and CPTII activities could explain results of enzymatic studies and immunoprecipitation experiments performed with both sets of patients. The mutations exhibited by "hepatic" and "muscular" cell lines would affect the expression of different proteins supporting CPTI and CPTII activities, respectively. Our results strengthen recent data advocating distinct proteins supporting CPT activities. Contrary to CPTII, CPTI activity is suppressed if assayed with detergents (6, 7, 9) . Antibodies raised against a purified protein supporting CPT activity assayable in detergent conditions do not recognize the protein supporting CPTI activity (9) , identified by its capacity to bind tetradecylglycidyl CoA, a specific inhibitor of CPTI activity. The mol wt of the protein supporting CPTI activity estimated either by SDS-PAGE (7) or by radiation inactivation experiments (8) , was nearly 90 000 D, whereas the mol wt of the protein bearing CPTII activity estimated by the same methods was nearly 70 000 D (7, 8) . As a consequence, CPT purified by classical methods using detergents (1 1-13, and Demaugre F, Cepanec C, Leroux JP, unpublished data) only supports CPTII activity. Moreover, it can be deduced from the data of Murthy and Pande (27) that proteins supporting CPTI and CPTII activities are not localized in the same subcellular structure: contrary to CPTII, CPTI activity might not be associated with the inner but with the external mitochondrial membrane.
As previously reported (28) , the absence of membrane components may decrease CPTI activity. As a consequence, one cannot exclude that CPTI deficiency might be the result of mutations concerning such components. Further investigations must be performed to clarify this point.
